Home › Urothelial (Transitional Cell) Carcinoma › Tennessee › Nashville
Pag-aaral pangklinika para sa Urothelial (Transitional Cell) Carcinoma sa Nashville, TN
Isang pag-aaral para sa Urothelial (Transitional Cell) Carcinoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Nagre-recruitPhase 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Nagre-recruitObservasyonal na pag-aaral
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- at 9 pa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Nagre-recruitPhase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Nagre-recruitPhase 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Nagre-recruitPhase 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Nagre-recruitPhase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Nagre-recruitPhase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Nagre-recruit
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Nagre-recruitPhase 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Nashville
Pag-aaral para sa Urothelial (Transitional Cell) Carcinoma sa ibang lungsod
- New York City, NY22 pag-aaral
- Houston, TX19 pag-aaral
- Dallas, TX18 pag-aaral
- Edison, NJ18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Queens, NY15 pag-aaral
- Chicago, IL14 pag-aaral
- Arlington, VA12 pag-aaral
- Boston, MA11 pag-aaral
- San Antonio, TX11 pag-aaral
- Austin, TX10 pag-aaral
- Orange, CA10 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Kanser sa Suso81 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Kanser ng Endometrium38 pag-aaral
- Melanoma33 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.